Live price temporarily unavailable.
Tenaya Therapeutics (TNYA) is a Health Care company. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Operating income | −$38.9M | −$72.8M | −$125.6M | −$131.2M | −$115.9M | −$93.3M |
| Net income | −$38.4M | −$72.7M | −$123.7M | −$124.1M | −$111.1M | −$90.6M |
| EPS (diluted) | −$39.50 | −$4.10 | −$2.76 | −$1.68 | −$1.31 | −$0.59 |
| Balance sheet | ||||||
| Cash and equivalents | $128.5M | $38.1M | $95.3M | $45.7M | $4.32M | $100.5M |
| Total assets | $148.2M | $314.2M | $278.9M | $170.5M | $119.9M | $146.9M |
| Total liabilities | $8.72M | $35.7M | $35.6M | $31.1M | $27.1M | $23.7M |
| Shareholders' equity | −$81.3M | $278.5M | $243.4M | $139.4M | $92.9M | $123.3M |
| Cash flow | ||||||
| Operating cash flow | −$35.4M | −$60.8M | −$104.4M | −$102.1M | −$90.5M | −$68.3M |
| Capital expenditure | $9.76M | $25.1M | $20.6M | $1.24M | $1.02M | $618.0K |
| Free cash flow | −$45.2M | −$85.9M | −$125.1M | −$103.3M | −$91.5M | −$68.9M |
| Share buybacks | $1.00K | $13.0K | — | — | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | $0 | $0 | — | — | $225.0K | $1.11M |
| Operating income | −$26.7M | −$24.7M | −$27.5M | −$24.1M | −$20.9M | −$20.8M | −$20.1M | −$44.1M |
| Operating margin | — | — | — | — | — | — | −8917.8% | −3971.9% |
| Net income | −$25.6M | −$23.8M | −$26.9M | −$23.3M | −$20.3M | −$20.2M | −$19.3M | −$43.4M |
| Net margin | — | — | — | — | — | — | −8565.3% | −3909.3% |
| EPS (diluted) | −$0.30 | −$0.27 | −$0.24 | −$0.14 | −$0.12 | −$0.09 | −$0.09 | −$0.20 |
| Balance sheet | ||||||||
| Cash and equivalents | $8.23M | $4.32M | $53.8M | $62.7M | $56.3M | $100.5M | $80.9M | $78.1M |
| Total assets | $140.6M | $119.9M | $144.0M | $122.2M | $105.0M | $146.9M | $135.1M | $93.5M |
| Total liabilities | $28.0M | $27.1M | $24.6M | $22.3M | $22.1M | $23.7M | $28.9M | $24.1M |
| Shareholders' equity | $112.6M | $92.9M | $119.4M | $99.8M | $82.9M | $123.3M | $106.2M | $69.4M |
| Cash flow | ||||||||
| Operating cash flow | −$19.8M | −$18.4M | −$23.1M | −$15.6M | −$15.6M | −$13.9M | −$19.2M | −$3.55M |
| Capital expenditure | $184.0K | $204.0K | $383.0K | $142.0K | $26.0K | $67.0K | $11.0K | $159.0K |
| Free cash flow | −$20.0M | −$18.6M | −$23.5M | −$15.8M | −$15.6M | −$14.0M | −$19.2M | −$3.71M |
From Tenaya Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Tenaya Therapeutics in our feed yet.